These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 26992841)

  • 21. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab.
    Baget-Bernaldiz M; Romero-Aroca P; Bautista-Perez A; Mercado J
    Doc Ophthalmol; 2017 Oct; 135(2):85-96. PubMed ID: 28779336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.
    Maguire MJ; Laidlaw A; Hammond C; Muqit MMK; Steel D; Dinah C; Lee E; Hillier R; Almeida G; Hussain R; Gordon-Bennet P; Hughes E; Alexander P; Vaideanu-Collins D; Jackson T
    JAMA Ophthalmol; 2024 Sep; 142(9):837-844. PubMed ID: 39115867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.
    Laugesen CS; Ostri C; Brynskov T; Lund-Andersen H; Larsen M; Vorum H; Sørensen TL
    Acta Ophthalmol; 2017 Feb; 95(1):28-32. PubMed ID: 27473397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
    Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
    Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
    Mitchell P; Bandello F; Schmidt-Erfurth U; Lang GE; Massin P; Schlingemann RO; Sutter F; Simader C; Burian G; Gerstner O; Weichselberger A;
    Ophthalmology; 2011 Apr; 118(4):615-25. PubMed ID: 21459215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
    Brown DM; Ou WC; Wong TP; Kim RY; Croft DE; Wykoff CC;
    Ophthalmology; 2018 May; 125(5):683-690. PubMed ID: 29336896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of ranibizumab on diabetic retinopathy severity and progression.
    Ip MS; Domalpally A; Hopkins JJ; Wong P; Ehrlich JS
    Arch Ophthalmol; 2012 Sep; 130(9):1145-52. PubMed ID: 22965590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
    Seo KH; Yu SY; Kim M; Kwak HW
    Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment.
    Bressler SB; Ayala AR; Bressler NM; Melia M; Qin H; Ferris FL; Flaxel CJ; Friedman SM; Glassman AR; Jampol LM; Rauser ME;
    JAMA Ophthalmol; 2016 Mar; 134(3):278-85. PubMed ID: 26746868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.
    Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG
    Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Vision Outcomes in Patients With DME and a Limited Early Visual Response to Ranibizumab in RIDE and RISE.
    Singh RP; Pieramici DJ; Wang PW; Gune S
    Ophthalmic Surg Lasers Imaging Retina; 2020 Apr; 51(4):210-218. PubMed ID: 32348537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.